We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biomarker Signatures Predict Aging Health Quality

By LabMedica International staff writers
Posted on 17 Jan 2017
A panel of 19 biomarkers in the blood was utilized to create molecular signatures that are able to predict how well an individual is aging and how severe the likelihood that he or she will develop an aging-related disease.

To establish these signatures, investigators at Boston University measured 19 blood biomarkers that included constituents of standard hematological measures, lipid biomarkers, and markers of inflammation and frailty in 4704 participants of the Long Life Family Study (LLFS). More...
The biomarkers were selected based upon their noted quantitative change with age and specificity for inflammatory, hematological, metabolic, hormonal, or kidney functions.

The LLFS is a family-based study that enrolled 4935 participants including subjects and siblings (30%), their offspring (50%), and spouses (20%), with ages between 30 and 110 years. Approximately 40% of enrolled participants were born before 1935 and had a median age at enrollment of 90 years and 45% participants were male. Almost 55% of participants from the subject generation (birth year prior to 1935) have died since enrollment, with a median age at death of 96 years. Mortality in the generation born after 1935 is lower (3%) and among these few that have died, median age at death is currently 69 years.

The investigators used an agglomerative algorithm to analyze distribution of the 19 biomarkers and then grouped LLFS participants into clusters that yielded 26 different biomarker signatures.

To test whether these signatures were associated with differences in biological aging, the investigators correlated them with longitudinal changes in physiological functions and incident risk of cancer, cardiovascular disease, type II diabetes, and mortality using longitudinal data collected in the LLFS. One signature was found to be associated with significantly lower mortality, morbidity, and better physical function relative to the most common biomarker signature in LLFS, while nine other signatures were associated with less successful aging, characterized by higher risks for frailty, morbidity, and mortality.

"Many prediction and risk scores already exist for predicting specific diseases like heart disease," said first author Dr. Paola Sebastiani, professor of biostatistics at Boston University. "Here, though, we are taking another step by showing that particular patterns of groups of biomarkers can indicate how well a person is aging and his or her risk for specific age-related syndromes and diseases. These signatures depict differences in how people age, and they show promise in predicting healthy aging, changes in cognitive and physical function, survival, and age-related diseases like heart disease, stroke, type II diabetes, and cancer."

The study was published in the January 6, 2017, online edition of the journal Aging Cell.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Elevated creatinine levels do not necessarily indicate impaired kidney function: pre-treatment cystatin C measurement is key to assessment (Image Credit: Data panels adapted from Watanabe H, et al. Clin Pharmacol Ther (2026). All icons were obtained from bioicons.com and modified.)

Cystatin C Testing Helps Distinguish Abemaciclib Effect from Kidney Injury

Kidney function monitoring in breast cancer care often relies on serum creatinine, a routine blood marker used to estimate renal function. However, creatinine increases in patients receiving abemaciclib... Read more

Hematology

view channel
Image: Mayo Clinic researchers used genetic data from nearly 50,000 participants to identify sickle cell and beta-thalassemia carrier traits, highlighting how population-scale testing can complement existing screening (Image Credit: Adobe Stock)

Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification

Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more

Microbiology

view channel
Image: The test uses serum or plasma from patients with suspected acute infection and symptoms lasting fewer than seven days and generates a score indicating the likelihood of bacterial infection. (Image Credit: Shutterstock)

Rapid Host-Response Assay Gains FDA Clearance to Help Distinguish Bacterial and Viral Infections

Bacterial and viral infections often cause similar symptoms, making early differentiation difficult in emergency and urgent care settings. Clinicians may need to begin treatment before traditional diagnostic... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The ExaccType ESR1 dPCR Kit uses digital PCR technology to detect key ESR1 mutations associated with acquired resistance to endocrine therapy. (Photo courtesy of  BIOTYPE)

Collaboration Expands Access to Tests for Cancer Treatment Resistance and Toxicity Risk

Precision medicine in oncology relies on molecular testing to identify biomarkers that can help guide treatment decisions. In hormone receptor-positive, HER2-negative metastatic breast cancer, ESR1 mutations... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.